<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01506700</url>
  </required_header>
  <id_info>
    <org_study_id>DXP 2012-01</org_study_id>
    <nct_id>NCT01506700</nct_id>
  </id_info>
  <brief_title>Real Time Optical Coherence Tomography (OCT) of Human Tissue</brief_title>
  <official_title>Real Time Optical Coherence Tomography (OCT) of Human Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diagnostic Photonics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Diagnostic Photonics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, prospective, study of an optical imaging device on approximately twenty&#xD;
      (20) subjects undergoing lumpectomies at one study site. In vivo and ex vivo imaging will be&#xD;
      performed on study subjects with results being compared to final pathology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-center, prospective, two-part open label study of an optical imaging&#xD;
      device on approximately twenty (20) subjects at one (1) study site. Patients scheduled to&#xD;
      undergo a lumpectomy will be recruited by the clinical investigators at the investigational&#xD;
      site in accordance with the inclusion and exclusion criteria. The study period per subject is&#xD;
      the time it takes to assess the in vivo and ex vivo breast tissue samples using the study&#xD;
      device during their lumpectomy.&#xD;
&#xD;
      All specimens will be marked with India ink and undergo standard post-operative histology,&#xD;
      and digital histology images corresponding to the inked locations will be obtained. The&#xD;
      images and the matched digitized post-operative histology images will then be randomized and&#xD;
      read by a blinded, independent pathologist. Sensitivity and specificity will be calculated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    additional recruitment not needed&#xD;
  </why_stopped>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Actual">July 17, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The sensitivity and specificity of Optical Coherence Tomography to identify whether or not tumor can be identified ex vivo on breast cancer specimens as compared to post-surgical histology conclusions.</measure>
    <time_frame>One week after surgery</time_frame>
  </primary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <description>Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Females with breast cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women 18 years of age or older&#xD;
&#xD;
          2. Signed ICF&#xD;
&#xD;
          3. Women who have been histologically diagnosed with invasive ductal carcinoma or&#xD;
             invasive lobular carcinoma of the breast prior to surgery&#xD;
&#xD;
          4. Planning breast preservation&#xD;
&#xD;
          5. Patients undergoing lumpectomy (partial mastectomy) procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multicentric disease (histologically diagnosed cancer in two different quadrants of&#xD;
             the breast)&#xD;
&#xD;
          2. Neoadjuvant systemic therapy&#xD;
&#xD;
          3. All T4 tumors&#xD;
&#xD;
          4. Previous radiation in the operated breast&#xD;
&#xD;
          5. Prior surgical procedure in the same quadrant&#xD;
&#xD;
          6. Implants in the operated breast&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
          8. Lactation&#xD;
&#xD;
          9. Participating in any other investigational study for either drug or device which can&#xD;
             influence collection of valid data under this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen A Boppart, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Illinois and Diagnostic Photonics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2012</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

